Milena Tome

Milena Tome

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Journal of Perinatology
Verified
Journal Article
Closed access
PDF file
MTMilena Tome
Milena Tome
EOEduardo A. de S. Orlandin
Eduardo A. de S. Orlandin
MZMariana T. Zinher
Mariana T. Zinher
SDSofia O. Dias
Sofia O. Dias
WFWalusa Assad Gonçalves Ferri
Walusa Assad Gonçalves Ferri
TIThaís Iwashita-Lages
Thaís Iwashita-Lages

17 March 2025 in Jornal de Pediatria
Verified
Journal Article
Open access
EOEduardo Antonio de Sousa Orlandin
Eduardo Antonio de Sousa Orlandin
TIThais Iwashita-Lages
Thais Iwashita-Lages
LOLuis Kanhiti Oharomari-Junior
Luis Kanhiti Oharomari-Junior
MTMilena Tome
Milena Tome
MZMariana Tosato Zinher
Mariana Tosato Zinher
WFWalusa Assad Gonçalves Ferri
Walusa Assad Gonçalves Ferri
This systematic review aimed to analyze, in neonates, the effects of high-frequency oscillatory ventilation (HFOV) with volume-targeted (VT) compared with conventional HFOV. The authors searched PubMed, EMBASE, Cochrane, and ClinicalTrials.gov from inception until August 4th, 2024, to identify studies comparing HFOV with and without VT in neonates under 44 weeks corrected age. Outcomes analyzed were VThf, amplitude and carbon dioxide partial pressure (PCO2) variability, episodes of hypoxemia, hypocarbia or hypercarbia, duration of mechanical ventilation, rates of bronchopulmonary dysplasia (BPD) or intraventricular hemorrhage (IVH), and mortality. ROB-2 and ROBINS were used for risk of bias assessment. This systematic review included 260 preterm infants from two crossover and four cohort studies. Five studies were considered as having a relevant risk of bias. Meta-analysis could not be performed, due to the differences in study design and incomplete reporting. The report of included studies indicates that HFOV with VT, compared with HFOV, may reduce VThf variability, hypocarbia and hypercarbia incidence. Findings on hypoxemia incidence and mechanical ventilation duration are mixed. Two studies found no difference in BPD rates, while one noted higher survival without BPD grades 2-3 under HFOV with VT. IVH, leukomalacia, and mortality outcomes were similar. Inclusion of VT during HFOV may reduce VThf variability, hypocarbia and hypercarbia incidence. However, there is a need for randomized trials to compare clinical outcomes from both ventilatory strategies.

27 February 2026 in Arquivos de Neuro-Psiquiatria
Verified
Journal Article
Open access
PDF file
LMLuana Miyahira Makita
Luana Miyahira Makita
GCGabriela das Graças dos Santos Carolino
Gabriela das Graças dos Santos Carolino
YSYuri Gubitose de Souza
Yuri Gubitose de Souza
HBHeloísa Carneiro Brito
Heloísa Carneiro Brito
MOMariana Oliveira
Mariana Oliveira
MPMario Fernando Prieto Peres
Mario Fernando Prieto Peres
Chronic migraine (CM) is often complicated by medication-overuse headache (MOH), worsening disability. Although withdrawal of overused medications is recommended, adherence is poor and relapse is frequent. Monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway may offer an effective preventive option without requiring discontinuation, but current evidence is limited by few and heterogeneous randomized controlled trials (RCTs). To systematically assess the efficacy and safety of anti-CGRP mAbs in treating CM with MOH (CM + MOH) under a conservative approach. The PubMed, Embase, and Cochrane Central databases were searched for RCTs comparing anti-CGRP mAbs with placebo in adults with CM + MOH. The primary outcome was the mean change in monthly migraine days (MMDs) at 3 months. The secondary outcomes included acute medication use, disability, drug overuse resolution, response rate, and adverse events (AEs). Random-effects models with Sidik-Jonkman estimator and Knapp-Hartung adjustments pooled effect sizes. We included seven RCTs, totalling 3,094 patients. Anti-CGRP mAbs significantly reduced MMDs (mean difference [MD] = -0.35; 95%CI: -0.43 to -0.26) and acute medication use (MD = -0.35; 95%CI: -0.51 to -0.19) compared with placebo. Higher rates, of ≥ 50%, of response (risk ratio [RR] = 1.94; 95%CI: 1.60–2.34) and drug overuse resolution (RR = 1.38; 95%CI: 1.04–1.83) were observed, with no significant increase in AEs (RR = 1.09; 95%CI: 0.85–1.40). Anti-CGRP mAbs were effective and well tolerated in CM + MOH, representing a viable alternative, especially for patients unable to discontinue acute medications. Further research should assess long-term outcomes and subgroup effects.

21 May 2026 in Liver International
Verified
Journal Article
Open access
IVIsabelle Castro Vitor
Isabelle Castro Vitor
MTMilena Tome
Milena Tome
WAWellgner Fernandes Oliveira Amador
Wellgner Fernandes Oliveira Amador
ISIgor Boechat Silveira
Igor Boechat Silveira
MLMarina de Assis Bezerra Cavalcanti Leite
Marina de Assis Bezerra Cavalcanti Leite
RMRodrigo Vieira Motta
Rodrigo Vieira Motta
Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485

9 January 2026
Verified
Journal Article
Open access
WAWellgner Fernandes Oliveira Amador
Wellgner Fernandes Oliveira Amador
IVIsabelle Castro Vitor
Isabelle Castro Vitor
MTMilena Tome
Milena Tome
DDDiogo Delgado Dotta
Diogo Delgado Dotta
RMRodrigo V Motta
Rodrigo V Motta
Selective IL-12/23p40 receptor antagonists (IL-12/23RA) show promise for treating moderate to severe ulcerative colitis (UC), but their efficacy and safety are not fully understood. Objective: This systematic review and meta-analysis assess the effectiveness and safety of IL-12/23RA in UC. A systematic search of PubMed, Embase, Cochrane, and ClinicalTrials.gov was performed in December 2024. Randomized controlled trials (RCTs) comparing IL-12/23RA to placebo in moderate to severe UC were included. Outcomes included clinical and endoscopic remission, response rates, and adverse events (AEs). Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were pooled using a random-effects model. Nine RCTs (3,808 patients in the induction phase; 1,734 in the maintenance phase) were analyzed. IL-12/23RA enhanced clinical remission (induction: RR 2.63; 95%CI 2.05-3.36; maintenance: RR 1.99; 95%CI 1.63-2.44; all P<0.01) and endoscopic remission (induction: RR 2.36; 95%CI 1.70-2.20; maintenance: RR 1.96; 95%CI 1.63-2.37; all P<0.01). IL-12/23RA reduced serious AE in the induction phase (RR 0.40; 95%CI 0.27-0.69; P<0.01), while there was no difference during maintenance (RR 0.75; 95%CI 0.31-1.84; P=0.53). No differences were observed in overall AEs or specific AEs like headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-12/23RA showed superior effectiveness and similar safety when compared to placebo in moderate to severe UC.

24 September 2026 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
ISIgor Boechat Silveira
Igor Boechat Silveira
LSLeonardo Corrêa Süffert
Leonardo Corrêa Süffert
GLGustavo André Pedral Diniz Leite
Gustavo André Pedral Diniz Leite
MTMilena Tome
Milena Tome
SLSarah Quick Lourenço de Lima
Sarah Quick Lourenço de Lima
GCGuilherme Grossi Lopes Cançado
Guilherme Grossi Lopes Cançado
Background/Aims: Cholestatic pruritus is a debilitating symptom with substantial placebo responses. We aimed to quantify this response and identify trial‐level moderators in randomized controlled trials of contemporary therapies. Methods: We performed a systematic review and meta‐analysis of placebo‐controlled trials evaluating ileal bile acid transporter inhibitors or PPAR agonists (searched through March 2026, with a supplementary search on 11 July 2026). Primary outcomes included the standardized mean change (SMC) of pruritus intensity, placebo response rate and mean difference (MD) in Numerical Rating Scale (NRS) and Worst–Itch NRS (WI‐NRS) scores. Secondary outcomes included PBC‐40 and 5‐D Itch scores. We used random‐effects models with Hartung–Knapp adjustment and meta‐regression. Results: Thirteen trials ( n = 548) were analysed. Across placebo groups, pruritus intensity decreased significantly from baseline during follow‐up periods of up to 52 weeks. The pooled SMC was −0.49 (95% CI, −0.72 to −0.27) overall, and −0.57 (95% CI, −0.81 to −0.33) for moderate‐to‐severe pruritus. Pooled response rates were 30.0% (overall) and 27.4% (moderate‐to‐severe). In moderate‐to‐severe patients, NRS showed a significant mean reduction of −1.62, whereas the WI‐NRS change (−0.65) was not statistically significant. Significant reductions occurred in the PBC‐40 itch domain (−2.02) and overall score (−9.13), while 5‐D Itch changes were non‐significant. None of the evaluated moderators were statistically significant. Conclusions: The magnitude of placebo‐associated improvement differed across outcome instruments and may affect estimates and interpretation of treatment effects in cholestatic‐pruritus trials. These findings may inform endpoint selection and assumptions used in future trial design. Trial Registration: PROSPERO registration number: CRD420261385974